HTL Biotechnology inaugurates a new production line dedicated to sterile Hyaluronic Acid
As part of National Biomanufacturing Day 2025, HTL Biotechnology inaugurates a new production line dedicated to Hyaluronic Acid.
Press releases
September 30, 2021
HTL launches a new bioproduction unit HTL4
Representing an investment of more than 50 million euros, this new unit dedicated to the bioproduction of pharmaceutical-grade hyaluronic acid represents a pivotal stage in the development of HTL and the largest investment ever made in the world for a biopolymer production unit.
It will enable HTL to become the largest producer of pharmaceutical-grade hyaluronic acid in the world and accelerate its international development.
Read more below.
To see our most recent news,
follow us on LinkedIn
Read more
news from us
-
Articles October 9, 2025HTL Biotechnology rallies for Pink October 2025
This October, HTL Biotechnology turned pink to support breast cancer prevention.
-
Articles September 19, 2025HTL Biotechnology wins the Responsible Care 2025 Award
HTL Biotechnology is the winner of the Responsible Care West Atlantic Trophy in the ‘Energy – Climate’ category for its project to reduce carbon emissions from distillation systems.
-
Articles September 13, 2025Looking Back at Our Presence at ESCRS 2025
The European Society of Cataract and Refractive Surgeons (ESCRS) is a unique opportunity each year to connect with our clients and partners while gaining insights into the key trends shaping the future of ophthalmology.